Next-Gen Incretin Challengers: Viking's Oral VK2735, Roche's CT-388, and AstraZeneca's Elecoglipron Phase 3 Progression
The competitive landscape for weight loss and cardiometabolic therapeutics is expanding rapidly beyond the Eli Lilly and Novo Nordisk duopoly. Clinical-stage challengers are advancing highly competitive assets, with AstraZeneca officially moving its oral small-molecule GLP-1 receptor agonist, elecoglipron (AZD5004), into an extensive Phase 3 global clinical programme following outstanding Phase 2b data.
AstraZeneca presented results from its VISTA (obesity/overweight) and SOLSTICE (type 2 diabetes) Phase 2b trials at the American Diabetes Association (ADA) 2026 Scientific Sessions, simultaneously publishing them in The Lancet on June 8, 2026.
AstraZeneca's Elecoglipron: Phase 2b Efficacy and Safety Profile
Elecoglipron is a once-daily, oral small-molecule GLP-1 receptor agonist. Unlike peptide-based oral drugs (which require strict fasting and water limits), elecoglipron is a small molecule that can be manufactured at scale with lower costs and possesses no food or fasting restrictions12, representing a major convenience advantage for patients.
- VISTA Trial (Obesity/Overweight, n=310): Adults receiving once-daily elecoglipron (75 mg) achieved a clinically meaningful and statistically significant average weight loss of 10.5% at 26 weeks (compared to 0.6% for placebo). Weight loss did not plateau, reaching 11.8% at 36 weeks (versus 0.3% with placebo). Up to 88.8% of participants on the 75 mg dose achieved at least 5% weight loss at 26 weeks.
- SOLSTICE Trial (Type 2 Diabetes, n=404): Adults on the 75 mg dose achieved an average HbA1c reduction of 1.9% at 26 weeks (versus 0.2% for placebo). An impressive 85% of patients reached an HbA1c of 6.5% or lower. Furthermore, type 2 diabetes patients experienced an average weight loss of 7.7% at 26 weeks.
- Safety and Tolerability: The safety profile was consistent with the GLP-1 class, with predominantly mild-to-moderate gastrointestinal adverse events (nausea, constipation, diarrhea, vomiting). The most common side effect on the 75 mg dose was nausea (55% in VISTA, 37% in SOLSTICE). Discontinuations due to adverse events were infrequent, and no liver safety or severe hypoglycemia signals were observed.
Broad Phase 3 Global Programme Launched
Based on these robust results, AstraZeneca is launching an extensive Phase 3 programme in the second half of 2026:
- EMBOLD Phase 3 Trials: Evaluating elecoglipron in adults with obesity or overweight, with and without type 2 diabetes.
- ELUMINATE Phase 3 Trials: Evaluating elecoglipron as a monotherapy and in combination with Farxiga (dapagliflozin, an SGLT2 inhibitor) for type 2 diabetes.
- Outcome Trials: Designed to evaluate long-term cardiovascular and kidney outcomes, leveraging AstraZeneca's deep commercial and clinical footprint in CVRM (Cardiovascular, Renal, and Metabolism) diseases.
AstraZeneca's aggressive Phase 3 entry, combined with Viking's oral VK2735 and Roche's CT-388, signals that the oral obesity market will become highly crowded and competitive by the late 2020s, challenging the early dominance of Lilly's Foundayo and Novo's Wegovy pill.3
-
An instance of Needle-free oral formulations capture a vast metabolic patient cohort completely distinct from injectable therapy users. — Next-generation oral metabolic tablets overcome the clinical and lifestyle barriers of needles, capturing massive new untreated populations. ↩︎
-
An instance of Strict fasting rules strip the convenience benefit from oral peptide weight-loss drugs. — It contrasts the high-convenience profile of next-generation small molecules with the rigid behavioral constraints that restrict peptide-based oral options. ↩︎
-
An instance of A regulatory compounding ban cannot shield the incretin duopoly from superior next-generation pipelines. — The rapid progression of competitive, needle-free oral candidates like elecoglipron threatens the early market dominance of Lilly and Novo's first-generation assets. ↩︎